Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GP IIb/IIIa blockade in elective percutaneous coronary intervention.

J P Dery1, R A Harrington, J E Tcheng

  • 1Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA.

Current Pharmaceutical Design
|February 18, 2004
PubMed
Summary

Platelet GP IIb/IIIa inhibitors reduce ischemic complications and improve survival in patients undergoing percutaneous coronary intervention (PCI). Despite evidence, their use in PCI remains inconsistent, warranting further discussion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reductions in sugar sales from soft drinks in the UK from 2015 to 2018.

BMC medicine·2020
Same author

Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add?

European heart journal·2018
Same author

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.

Thrombosis and haemostasis·2014
Same author

Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Dose selection for a direct and selective factor IXa inhibitor and its complementary reversal agent: translating pharmacokinetic and pharmacodynamic properties of the REG1 system to clinical trial design.

Journal of thrombosis and thrombolysis·2011

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Platelet GP IIb/IIIa inhibitors are established in reducing ischemic complications during percutaneous coronary intervention (PCI).
  • Recent data indicate these inhibitors also enhance short- and long-term survival post-PCI.

Purpose of the Study:

  • To review the scientific basis for using GP IIb/IIIa inhibitors in PCI.
  • To discuss controversies surrounding their administration in elective PCI.

Main Methods:

  • Review of cumulative scientific evidence over the past ten years.
  • Analysis of mortality data from over 20,000 patients in randomized clinical trials.

Main Results:

  • Consistent evidence supports GP IIb/IIIa inhibitors in reducing ischemic events.

Related Experiment Videos

  • Mortality data suggest improved survival rates with GP IIb/IIIa blockade post-PCI.

    • Conclusions:

    • GP IIb/IIIa inhibitors are crucial for managing PCI patients.
    • Inconsistent administration highlights a need to address clinical practice gaps and controversies.